Xenograft models and drug treatment

Patient-derived xenografts from SCLC circulating tumor cells or tumor biopsies were developed as previously described (Augert et al. 2019). Cells were reinjected as 100-μL aliquots of a 1:1 mixture of matrigel and dissociated cells into the flanks of NSG mice. Treatments of either MLN4924 or vehicle control were started at a flank tumor volume size of ∼150–200 mm³. Mice were administered MLN4924 or vehicle control at 60 mg/kg once daily for 15 d and individual flank tumors measured using calipers. At 15 d, tumors were resected after euthanasia of the mice.